Name | Fairway Oaks Center |
---|---|
Location | 13806 N 46th St, Tampa, Florida |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 120 |
Occupancy Rate | 62.42% |
Medicare ID (CCN) | 105305 |
Legal Business Name | Fairway Oaks Center Llc |
Ownership Type | For Profit - Limited Liability Company |
NPI Number | 1285622209 |
Organization Name | FAIRWAY OAKS CENTER, LLC |
Doing Business As | FAIRWAY OAKS CENTER |
Address | 13806 N 46th St, Tampa, FL 33613 |
Phone Number | 813-977-4214 |
News Archive
Shire plc, the global specialty biopharmaceutical company, announces that its subsidiaries Shire Development Inc. and Shire Pharmaceutical Development Inc. have filed a lawsuit in the U.S. District Court for the District of Delaware against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals, Inc. for the infringement of U.S. Patent No. 6,773,720.
Developed countries "gave more aid to poorer countries than ever before in 2010, despite facing big budget gaps and rising debt levels," according to data released on Wednesday by the Organization for Economic Cooperation and Development (OECD), Dow Jones Newswires/Wall Street Journal reports.
Patients with advanced colorectal tumors without mutations in the RAS genes derive substantial benefit from anti-EGFR therapies; however, the disease eventually progresses, leaving these patients with few alternative therapeutic options.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 8 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Shire plc, the global specialty biopharmaceutical company, announces that its subsidiaries Shire Development Inc. and Shire Pharmaceutical Development Inc. have filed a lawsuit in the U.S. District Court for the District of Delaware against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals, Inc. for the infringement of U.S. Patent No. 6,773,720.
Developed countries "gave more aid to poorer countries than ever before in 2010, despite facing big budget gaps and rising debt levels," according to data released on Wednesday by the Organization for Economic Cooperation and Development (OECD), Dow Jones Newswires/Wall Street Journal reports.
Patients with advanced colorectal tumors without mutations in the RAS genes derive substantial benefit from anti-EGFR therapies; however, the disease eventually progresses, leaving these patients with few alternative therapeutic options.
A new imaging test may provide the ability to identify ovarian cancer patients who are candidates for an emerging treatment that targets a key enzyme cancer cells need to survive.
› Verified 8 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 2 |
Total Amount of Fines in Dollars | $41077 |
Number of Payment Denials | 1 |
Total Number of Penalties | 3 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 8.42 | 14.46 |
Percentage of long-stay residents who lose too much weight | 1.39 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 59.32 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 0.96 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0.33 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 0.6 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.5 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 17.23 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 84.85 | 83.88 |